1-20 of 32
Michael O'Dwyer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

NK Cell States in Multiple Myeloma: Pathways to Novel Immunotherapies

Jacopo Umberto Verga, Eva Szegezdi, Pilib Ó Broin, Michael O'Dwyer, Micheál Ó Dálaigh, Wanshan Hu
Journal: Blood
Blood (2024) 144 (Supplement 1): 6857.
https://doi.org/10.1182/blood-2024-210297
Published: 2024
Journal Articles

Increased Expression of the Sialyltransferase Gene ST3GAL1 Predicts Lack of Sustained MRD Negativity and Increased Risk of Progression in Newly Diagnosed, Transplant Eligible Multiple Myeloma Patients in the Maintenance/Observation Phase of Cassiopeia Study

Michael O'Dwyer, Aideen Edele Ryan, Aoise O'Neill, Catherine Guerin-Charbonnel, Soraya Wuilleme, Jill Corre, Herve Avet Loiseau, Li Peng, Philippe Moreau, Stephane Minvielle
Journal: Blood
Blood (2024) 144 (Supplement 1): 250.
https://doi.org/10.1182/blood-2024-193955
Published: 2024
Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study

Philippe Moreau, Thierry Facon, Saad Usmani, Nizar Jacques Bahlis, Noopur Raje, Torben Plesner, Robert Z. Orlowski, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, Katja Weisel, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Huiling Pei, Maria Krevvata, Robin Carson, Fredrik Borgsten, Shaji K Kumar
Journal: Blood
Blood (2022) 140 (Supplement 1): 7297–7300.
https://doi.org/10.1182/blood-2022-163494
Published: 2022
Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis

Thierry Facon, Shaji K Kumar, Katja Weisel, Saad Usmani, Philippe Moreau, Torben Plesner, Robert Z. Orlowski, Nizar Jacques Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, Noopur Raje, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Huiling Pei, Robin Carson, Fredrik Borgsten, Hartmut Goldschmidt
Journal: Blood
Blood (2022) 140 (Supplement 1): 10133–10136.
https://doi.org/10.1182/blood-2022-163555
Published: 2022
Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study

Shaji K Kumar, Philippe Moreau, Nizar Jacques Bahlis, Thierry Facon, Torben Plesner, Robert Z. Orlowski, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, Katja Weisel, Noopur Raje, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Huiling Pei, Maria Krevvata, Robin Carson, Fredrik Borgsten, Saad Usmani
Journal: Blood
Blood (2022) 140 (Supplement 1): 10150–10153.
https://doi.org/10.1182/blood-2022-163335
Published: 2022
Journal Articles

miR-130b and miR-128a are essential lineage-specific codrivers of t(4;11) MLL-AF4 acute leukemia

Camille Malouf, Eric T. B. Antunes, Michael O’Dwyer, Hélène Jakobczyk, Franziska Sahm, Sophie-Luise Landua, Richard A. Anderson, Abdenour Soufi, Christina Halsey, Katrin Ottersbach
Journal: Blood
Blood (2021) 138 (21): 2066–2092.
https://doi.org/10.1182/blood.2020006610
Published: 2021
Includes: Supplemental data
Journal Articles

Low Dose Cyclophosphamide in Combination with Elotuzumab - a Novel Immunotherapeutic Strategy for Multiple Myeloma

Claire L Feerick, Kevin Lynch, Janusz Krawczyk, Michael O'Dwyer, Aideen Ryan
Journal: Blood
Blood (2021) 138 (Supplement 1): 2664.
https://doi.org/10.1182/blood-2021-152432
Published: 2021
Journal Articles

Single Cell Transcriptomics Revealed Molecular Alterations in AML Cell Clusters Relevant to Refractory Disease at Relapse

Sarah Ennis, Alessandra Conforte, Sukhraj Pal Singh Dhami, Philippe Krebs, Michael O'Dwyer, Eva Szegezdi
Journal: Blood
Blood (2021) 138 (Supplement 1): 3316.
https://doi.org/10.1182/blood-2021-153910
Published: 2021
Journal Articles

Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)

Thierry Facon, Shaji K. Kumar, MD, Torben Plesner, MD DSc, Robert Z. Orlowski, MD PhD, Philippe Moreau, Nizar Bahlis, MD, Supratik Basu, MBBS, MD FRCP, FRCPath, Hareth Nahi, MD PhD, Cyrille Hulin, MD, Hang Quach, MDFRACP,FRCPA,MBBS, Hartmut Goldschmidt, MD, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, MD FRCPC, Katja Weisel, MD, Joseph R. Mace, Tahamtan Ahmadi, Christopher Chiu, PhD, Jianping Wang, Rian Van Rampelbergh, Clarissa M. Uhlar, Rachel Kobos, MD, Ming Qi, MD PhD, Saad Z. Usmani, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): LBA-2.
https://doi.org/10.1182/blood-2018-120737
Published: 2018
Journal Articles

Weekly CyborD-DARA Is a Safe and Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Preliminary Results of the Early Phase 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study

Cian McEllistrim, MD, Mary R Cahill, MD, Philip Murphy, PhD BPharm, Vitaliy Mykytiv, MD, John Quinn, Amanda Bray, Jessica Walsh, Elizabeth Lenihan, Tara Kenny, Grace Hirakata, Imelda Parker, Andres Hernando, Michael O'Dwyer, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3163.
https://doi.org/10.1182/blood.V130.Suppl_1.3163.3163
Published: 2017
Journal Articles

Patient Data Supports the Rationale of Low Dose Cyclophosphamide to Potentiate the Anti-Myeloma Activity of Daratumumab through Augmentation of Macrophage-Induced ADCP

Serika Naicker, BSc, PhD, Athina Rigalou, BSc MSc, Cian McEllistrim, MB, BCh, BAO, Alessandro Natoni, PhD, Christopher Chiu, Kate Sasser, PhD, Aideen Ryan, BSc,PhD, Michael O'Dwyer, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 121.
https://doi.org/10.1182/blood.V130.Suppl_1.121.121
Published: 2017
Journal Articles

Mesenchymal Stromal Cell Sialylation Enhances Immune Suppression in Multiple Myeloma

Kevin Lynch, BSc, MSc, O'Malley Grace, BSc, Aideen Ryan, BSc,PhD, Thomas Ritter, BSc, PhD, Michael O'Dwyer, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 124.
https://doi.org/10.1182/blood.V130.Suppl_1.124.124
Published: 2017
Journal Articles

GMI-1271 Improves Efficacy and Safety of Chemotherapy in R/R and Newly Diagnosed Older Patients with AML: Results of a Phase 1/2 Study

Daniel J. DeAngelo, MD, Brian A Jonas, MD PhD, Jane L. Liesveld, MD, Dale L. Bixby, Anjali S. Advani, MD, Paula Marlton, MBBS, Michael O'Dwyer, MD, John L Magnani, PhD, Helen M. Thackray, MD, Pamela S. Becker, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 894.
https://doi.org/10.1182/blood.V130.Suppl_1.894.894
Published: 2017
Journal Articles

Interleukin-6 Drives Multiple Myeloma Progression through Upregulating of CD147/Emmprin Expression and Its Sialylation

Yanmeng Wang, Rong Fan, Li Lei, PhD, Aiying Wang, Xiaman Wang, Shen Ying, Hongli Chen, Caoilfhionn Connolly, MD, Kim De Veirman, Aili He, MD, Karin Vanderkerken, PhD, Michael O'Dwyer, MD, Jinsong Hu, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3037.
https://doi.org/10.1182/blood.V130.Suppl_1.3037.3037
Published: 2017
Journal Articles

Targeting Siglec-7: A Novel Immunotherapeutic Approach to Potentiate the Cytotoxic Functions of Natural Killer Cells Against Multiple Myeloma

John Daly, MSc, Tony Duggan, BSc, Jinsong Hu, PhD, Alessandro Natoni, PhD, Subhashis Sarkar, PhD, Lucy Kirkham-McCarthy, MSc, Cian McEllistrim, MD, Janusz Krawczyk, MD, Michael O'Dwyer, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1799.
https://doi.org/10.1182/blood.V130.Suppl_1.1799.1799
Published: 2017
Journal Articles

Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Steven Coutre, MD, John C. Byrd, MD, Peter Hillmen, Jacqueline C. Barrientos, MD, Paul M. Barr, Stephen Devereux, PhD FRCP, FRCPath, Tadeusz Robak, MD PhD, Thomas J. Kipps, MD, PhD, Anna Schuh, MDPhD, Carol Moreno, MD, Richard R. Furman, Jan Burger, MD PhD, Michael O'Dwyer, MD, Paolo Ghia, Rudolph Valentino, PharmD, Samuel Suzuki, MS, MBA, Joi Ninomoto, PharmD, Danelle F. James, MD MAS, Susan M. O'Brien, MD
Journal: Blood
Blood (2016) 128 (22): 4383.
https://doi.org/10.1182/blood.V128.22.4383.4383
Published: 2016
Journal Articles

Estimating the Relative Effectiveness of Treatments in Relapsed/Refractory Multiple Myeloma through a Systematic Review and Network Meta-Analysis

Kai Ruggeri, PhD, Áine Maguire, MSc, Susanne Schmitz, PhD, Elisa Haller, MSc, Cathal Walsh, PhD, Jack Bowden, PhD, Isla Kuhn, Ayesha Khan, PhD, Gordon Cook, MD PhD, Michael O'Dwyer, MD
Journal: Blood
Blood (2015) 126 (23): 2103.
https://doi.org/10.1182/blood.V126.23.2103.2103
Published: 2015
Journal Articles

The Dual PIM/PI3-K Inhibitor Ibl-202 Overcomes Microenvironmental Mediated Resistance in Multiple Myeloma and Prevents PIM1 Induced CXCR4 Upregulation

Mairead Reidy, PhD, Marianne VanDijk, PhD, Michael O'Neill, PhD, Michael O'Dwyer, MD FRCPI, FRCPath
Journal: Blood
Blood (2015) 126 (23): 5350.
https://doi.org/10.1182/blood.V126.23.5350.5350
Published: 2015
Journal Articles

Results from the International, Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2 TM )

Alessandra Tedeschi, MD, Paul M. Barr, MD, Tadeusz Robak, MD PhD, Carolyn Owen, MD, Paolo Ghia, MD PhD, Osnat Bairey, MD, Peter Hillmen, MB, ChB, PhD, Nancy L Bartlett, MD, Jianyong Li, MD, David Simpson, MBBS, Sebastian Grosicki, MD PhD, Stephen Devereux, FRCP, FRCPath, PhD, Helen McCarthy, FRCP, FRCPath, PhD, Steven Coutre, MD, Hang Quach, MD, Gianluca Gaidano, MD PhD, Zvenyslava Maslyak, MD, Don A. Stevens, MD, Ann Janssens, MD, Fritz Offner, MD PhD, Jiří Mayer, MD, Michael O'Dwyer, MD, Andrzej Hellmann, MD PhD, Anna Schuh, MD PhD, Tanya Siddiqi, MD, Aaron Polliack, MD, Constantine S. Tam, MBBS, Michael Keating, MBBS, Deepali Suri, MS, Cathy Zhou, MS, Fong Clow, ScD, Lori Styles, MD, Danelle F. James, MD MAS, Thomas J. Kipps, MD, PhD, Jan A. Burger, MD PhD
Journal: Blood
Blood (2015) 126 (23): 495.
https://doi.org/10.1182/blood.V126.23.495.495
Published: 2015
Journal Articles

Clinical Characteristics, Treatment and Outcomes for Patients with Myelodysplastic Syndromes and Chromosome 5q Abnormalities in the Republic of Ireland

Su Wai Maung, MBBS, MRCP(UK), Cian McEllistrim, MRCPI, Amjad Hayat, MBBS, MRCP, FRCPath, PhD, Margaret Murray, FRCPath, Michael O'Dwyer, MD, Patrick Thornton, FRCPath, Emma Groarke, MRCPI, Denis O'Keeffe, MD MRCPath, Maeve Leahy, MD MRCPath, Aine Burke, MRCP,MD, Peter O'Gorman, Carmel Weldon, M.Sc, MRCPI, Gerard Crotty, MD FRCPath, Meegahage Ratnakanthi Perera, MDMRCPath,MBBS, Cathie Burke, RN, Johnny McHugh, FRCPath, Helen Enright, MD FRCPI, FRCPath, Ronan Desmond, MD FRCPath
Journal: Blood
Blood (2015) 126 (23): 5258.
https://doi.org/10.1182/blood.V126.23.5258.5258
Published: 2015